UNCY Unicycive Therapeutics, Inc.

Nasdaq unicycive.com


$ 5.92 $ 0.15 (2.6 %)    

Tuesday, 18-Nov-2025 15:58:05 EST
QQQ $ 599.40 $ 0.00 (0 %)
DIA $ 462.20 $ 0.00 (0 %)
SPY $ 662.93 $ 0.00 (0 %)
TLT $ 88.93 $ 0.00 (0 %)
GLD $ 378.15 $ 0.00 (0 %)
$ 5.92
$ 5.69
$ 5.80 x 100
$ 6.70 x 500
-- - --
$ 3.71 - $ 11.00
433,279
na
106.95M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-28-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-16-2023 03-31-2023 10-Q
12 03-31-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-11-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-unicycive-therapeutics-raises-price-target-to-22

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and raises ...

 unicycive-therapeutics-plans-to-resubmit-nda-for-oxylanthanum-carbonate-by-year-end

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...

 benchmark-maintains-speculative-buy-on-unicycive-therapeutics-raises-price-target-to-21

Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the pric...

 unicycive-therapeutics--became-aware-of-securities-class-action-lawsuit

-SEC Filing

 unicycive-therapeutics-q2-eps-052-beats-078-estimate

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate o...

 fda-raises-manufacturing-concerns-delays-unicycives-kidney-disease-drug-approval

FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ma...

 the-fda-issues-complete-response-letter-for-unicycive-therapeutics-new-drug-application-for-oxylanthanum-carbonate-to-treat-hyperphosphatemia-in-patients-with-chronic-kidney-disease-on-dialysis

Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxyl...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION